Key result
Ischaemia-modified albumin levels did not differ between patients with clinically stable dilated cardiomyopathy and normal subjects.
Why the study?
Are ischaemia-modified albumin (IMA) levels elevated in patients with compensated heart failure due to dilated cardiomyopathy compared to normal volunteers?
Case-Control (n=84)
Are ischaemia-modified albumin (IMA) levels elevated in patients with compensated heart failure due to dilated cardiomyopathy compared to normal volunteers?
Ischaemia-modified albumin is not elevated in stable dilated cardiomyopathy compared to healthy controls, but its levels correlate with heart failure severity.
Answers are grounded in this paper and cite their sources.
IMA not useful to distinguish stable dilated cardiomyopathy from controls; leaves open a severity biomarker role.
BACKGROUND: Biomarkers of myocardial necrosis may be increased in patients with chronic heart failure. We investigated whether ischaemia-modified albumin (IMA), a marker of ischaemia, is also elevated in patients with compensated heart failure, due to dilated cardiomyopathy (DCM). METHODS: We studied 42 patients with DCM and an equal number of age-matched normal volunteers. We assessed IMA serum levels with the albumin cobalt binding test. RESULTS: IMA was 89.9 +/- 13.1 (71-117) KU/L in the patient group and 93.9 +/- 9.9 (76-122) KU/L in the control group, with no significant difference between the two (P = 0.11). However, IMA differed significantly according to the New York Heart Association classification (P = 0.003) and was negatively correlated with the left ventricular ejection fraction (r = -0.40, P = 0.014). CONCLUSIONS: We conclude that IMA, a marker of ischaemia, does not differ in patients with clinically stable DCM compared with normal subjects, but varies significantly in relation to the severity of the disease.
No takes yet. Share an insight, caveat, or question.
Sbarouni et al. (2009) conducted a case-control in Dilated cardiomyopathy (n=84). Dilated cardiomyopathy vs. Age-matched normal volunteers was evaluated on Ischaemia-modified albumin (IMA) serum levels (p=0.11). Ischaemia-modified albumin levels did not differ between patients with clinically stable dilated cardiomyopathy and normal subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: